Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADIM II: Neo-adjuvant Chemo/Immunotherapy vs Chemotherapy in NSCLC
NCT03838159Phase 2Active, not recruiting
- Sponsor
- Fundación GECP
- Start
- May 2019
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fundación GECP. Primary endpoint: Pathological Complete Response up to 45 months. Started May 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03838159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838159.